Case Study: Advancing Treatment for Rare Neuromuscular Diseases through Gene Therapy – Inside REGENXBIO’s Pipeline
Time: 2:30 pm
day: Day 1- Clinical 2
Details:
• Leveraging the NAV AAV platform to develop gene therapies for rare neuromuscular diseases, aiming to provide long-lasting, single administration treatments
• Highlighting leading candidates in development to address conditions like Duchenne muscular dystrophy DMD, with innovative approaches that target underlying genetic causes
